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Introduction {#s1}
============

Colorectal cancer (CRC) in young age is a topic issue in oncology for many reasons. First, the sharp increase in the number of young patients with CRC diagnosed in last decades reported in several countries. The 2010 Annual Report to the Nation on Cancer celebrated a steady decline in the incidence of CRC in USA [@pone.0102004-Edwards1]. In sharp contrast to overall trends, the incidence of CRC in young patients appears to be increasing [@pone.0102004-Edwards1], [@pone.0102004-OConnell1], [@pone.0102004-OConnell2].The incidence of the disease, considering patients aged between 20--40 years of age increased by 17% during the period between 1973 and 1999 [@pone.0102004-OConnell1]. Moreover, the prognosis of CRC in young patients remains much controversies. Majority of studies in the literature used the cutoff age of 40 years to denote a young patients with CRC [@pone.0102004-OConnell2], [@pone.0102004-Neufeld1], [@pone.0102004-Karsten1], [@pone.0102004-Taylor1], [@pone.0102004-Li1]. Various studies have reported poorer prognosis among young patients with CRC [@pone.0102004-Taylor1], [@pone.0102004-Cusack1], [@pone.0102004-Marble1]. Our previous study and some other authors demonstrated young patients with CRC treated with surgery appear to have a higher cancer specific survival (CSS) rate than elderly ones [@pone.0102004-Li1], [@pone.0102004-Li2], [@pone.0102004-Schellerer1]. For young age is an inherent characteristic of wider age subgroups with potential heterogeneous.In this study, we updated our previous information about young patients with colon cancer (CC) and decided to evaluate four subgroups of patients according to four different age ranges, below 25 years, 26--30 years, 31--35 years and 36--40 years. Aim of our study was to analyze biological and clinical features and CSS of these four age-groups of young patients (below 40 years) with CC after surgery resection in Surveillance, Epidemiology, and End Results (SEER) population-based data.

Patients and Methods {#s2}
====================

Patients {#s2a}
--------

The SEER Cancer Statistics Review (<http://seer.cancer.gov/data/citation.html>), a report on the most recent cancer incidence, mortality, survival, prevalence and lifetime risk statistics, is published annually by the Data Analysis and Interpretation Branch of the National Cancer Institute, MD, and USA. The current SEER database consists of 17 population-based cancer registries that represent approximately 28% of the population in the United States. The SEER data contain no identifiers and are publicly available for studies of cancer-based epidemiology and survival analysis [@pone.0102004-Li2], [@pone.0102004-Gao1], [@pone.0102004-Golan1], [@pone.0102004-Gondos1].

Cases of invasive CC (C18.0-19.9) diagnosed between 1988 and 2005 were extracted from the SEER database (SEER\*Stat 8.1.2) according to the Site Recode classifications. Histological type were limited to adenocarcinoma (8150/3, 8210/3, 8261/3, 8263/3), mucinous adenocarcinoma (8480/3), and signet ring cell carcinoma (8490/3). Only patients aged between 18 and 40 years old and who\'s CC was a single primary tumor were included into the current study. Patients diagnosed after 2006 were excluded to ensure an adequate follow-up time. Other exclusion criterions were as follows: no lymph nodes (LNs) examined pathologically, synchronous distance metastases.

This study was based on the publicly available data from the SEER database and we had got the permission to access these research data (Reference number: 12768-Nov 2012). It didn\'t include interaction with human subjects or use personal identifying information. The study did not require informed consent and was approved by the Review Board of Fudan University Shanghai Cancer Center, Shanghai, China.

Statistical analysis {#s2b}
--------------------

Age, sex, race, extension of primary tumor invasion, total number of LNs examined, number of involved LNs, histological grade, survival time, and colon cancer-cause specific death (CCSS) were extracted from SEER database. All cases were restaged according to the criteria described in the American Joint Committee on Cancer (AJCC) Cancer Staging Manual (7th edition, 2010). And young patients with CC were divided into four subgroups according to four different age ranges: group 1 (below 25 years), group 2 (26--30 years), group 3 (31--35 years) and group 4 (36--40 years). The primary endpoint of this study was CCSS which was calculated from the date of diagnosis to the date of cancer specific death. Deaths attributed to the CC of interest are treated as events and deaths from other causes are treated as censored observation. Survival curves were generated using Kaplan-Meier estimates, differences between the curves were analyzed by log-rank test. Multivariable Cox regression models were built for analysis of risk factors for survival outcomes. All of the statistical analyses were done using the statistical software package SPSS for Windows, version 17 (SPSS Inc, Chicago, IL). Statistical significance was set at two-sided P\<0.05.

Results {#s3}
=======

Patient characteristics {#s3a}
-----------------------

We identified 2,861 eligible young patients with CC in SEER database during the 18-year study period (between 1988 and 2005), which included 171 patients in group 1 (below 25 years), 375 patients in group 2 (26--30 years), 773 patients in group 3 (31--35 years) and 1542 patients in group 4 (36--40 years). There were 1,529 (53.4%) males and 1,332 (46.6%) females. The median age was 36. The median follow-up period was 87 (IQR 59-134) months. Patient demographics and pathological features are summarized in [Table 1](#pone-0102004-t001){ref-type="table"}.

10.1371/journal.pone.0102004.t001

###### Characteristics of Patients from SEER Database by age.

![](pone.0102004.t001){#pone-0102004-t001-1}

                                                      Group 1   Group 2   Group 3   Group 4  
  ----------------------------------------- -------- --------- --------- --------- --------- ---------
  Media follow up (mo)                         87       72        85        89        89      \<0.001
  (IQR)                                      59-134   32-103    44-130    60-135    61-138   
  Years of diagnosis                                                                           0.154
  1988--1993                                  432       14        62        114       242    
  1994--1999                                  665       36        89        182       358    
  2000--2003                                  1764      121       224       477       942    
  Sex                                                                                          0.284
  male                                        1529      93        183       421       832    
  female                                      1332      78        192       352       710    
  Race                                                                                         0.792
  Caucasian                                   2047      117       264       566      1100    
  African American                            442       28        64        110       240    
  Others[\*](#nt101){ref-type="table-fn"}     365       26        47        94        198    
  Pathological grading                                                                         0.002
  High/Moderate                               2042      114       243       541      1144    
  Poor/undifferentiation                      713       50        120       206       337    
  Unknown                                     106        7        12        26        61     
  Histological Type                                                                           \<0.001
  Adenocarcinoma                              2267      115       281       630      1241    
  Mucinous/Signet-ring cancer                 587       55        91        142       299    
  AJCC stage                                                                                   0.002
  I                                           251       12        19        67        153    
  II                                          1184      60        141       324       659    
  III                                         1426      99        215       382       730    
  No. of LNs retrieval                       19.34     24.21     20.32     19.45     18.50    \<0.001
  No. of LNs metastasis                       2.17     3.07      2.62      2.27      1.90     \<0.001
  Current Standard                                                                           
  \<12                                        833       37        87        224       485      0.002
  ≥12                                         2028      134       288       549      1057    

\*including other (American Indian/AK Native, Asian/Pacific Islander) and unknowns.

Clinicopathological differences between the four groups {#s3b}
-------------------------------------------------------

When compared among four subgroups, it was investigated that significant differences were found among the pathological grading (more poor or undifferentiation in grade in group 1, p = 0.002), histological type (more mucinous/signet-ring cancer in group 1, p\<0.001), AJCC stage (more stage III in group 1, p = 0.002), current standard (more cases with ≥12 LNs dissected in group 1, p = 0.002). The mean number of LNs examined and positive LNs were 24.21 and 3.07 in group 1, 20.32 and 2.62 in group 2, 19.45 and 2.27 in group 3, 18.50 and 1.90 in group 4, respectively. All of them had statistical difference (p\<0.001). As regard to year of diagnosis (p = 0.154), sex (p = 0.284) and race (p = 0.792), no significant differences between four groups were found. The difference in the median follow-up times, which is a reflection of the survival experience of these four groups, also had statistical difference (p\<0.001). ([Table 1](#pone-0102004-t001){ref-type="table"})

Impact of age on survival outcomes in young patients with CC {#s3c}
------------------------------------------------------------

The 5-year CCSS was 71.0% in group 1, 75.1% in group 2, 80.6% in group 3 and 82.5% in group 4, which had significant difference in univariate log-rank test (P = 0.002) ([Fig. 1](#pone-0102004-g001){ref-type="fig"}). Besides, African race (P = 0.019), poor or undifferentiation tumor grade (P\<0.001), mucinous/signet-ring cancer (P\<0.001), higher AJCC stage (P\<0.001), and less number in LNs dissection (p\<0.001) were identified as significant risk factors for poor survival on univariate analysis ([Table 2](#pone-0102004-t002){ref-type="table"}). When multivariate analysis with Cox regression was performed, we convinced the following five factors as independent prognostic factors ([Table 3](#pone-0102004-t003){ref-type="table"}). These included age (group 3, HR 0.681, 95%CI 0.479--0.932, P = 0.017; group 4, HR 0.676, 95%CI 0.503--0.909, P = 0.010, using group 1 as reference), while the risk between group 1 and group 2 was not statistical difference (P = 0.186). Race (African American, HR 1.381,95%CI 1.130--1.687 P = 0.002; others, HR 1.14, 95%CI 0.885--1.403, P = 0.357, using Caucasian as reference), pathological grading (poor/undifferentiation tumor, HR 1.520, 95%CI 1.286--1.797, P\<0.001, using high/moderate tumor as reference), AJCC stage (stage II, HR 5.076, 95%CI 2.241--11.496, P\<0.001; stage III, HR 17.047, 95%CI 7.609--38.190, P\<0.001, using stage I as reference), current standard (retrieval LNs≥12, HR 0.620, 95%CI 0.529--0.727, P\<0.001, using retrieval LNs\<12 as reference). And histological type of tumor was not a prognostic factor according to multivariate survival analyses (P = 0.057) ([Tables 3](#pone-0102004-t003){ref-type="table"}).

![Survival curves in colon patients according to four age subgroups.\
Group 1 vs. group 2, *χ2 = 0.893, P = 0.345*; group 1 vs. group 3, *χ2 = 7.539, P = 0.006*. gropu 1 vs. group 4, *χ2 = 9.937, P = 0.002*; group 2 vs. group 3, *χ2 = 4.685, P = 0.030*. *group 3* vs. group 4, *χ2 = 7.052, P = 0.008*; group 3 vs. group 4, *χ2 = 0.075, P = 0.785*.](pone.0102004.g001){#pone-0102004-g001}
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###### Univariate survival analyses of CC patients according to various clinicopathological variables.

![](pone.0102004.t002){#pone-0102004-t002-2}

  Variable                                    n     5-year CCSS (%)   Log rank χ^2^ test      P
  ----------------------------------------- ------ ----------------- -------------------- ---------
  Years of diagnosis                                                        5.398           0.067
  1988--1993                                 432         76.8%                            
  1994--1999                                 665         79.5%                            
  2000--2003                                 1764        81.6%                            
  Sex                                                                       0.278           0.598
  male                                       1529        80.8%                            
  female                                     1332        79.8%                            
  Age                                                                       15.261          0.002
  ≤25                                        171         71.0%                            
  26--30                                     375         75.1%                            
  31--35                                     773         80.6%                            
  36--40                                     1542        82.5%                            
  Race                                                                      7.933           0.019
  Caucasian                                  2047        81.6%                            
  African American                           442         76.4%                            
  Others[\*](#nt102){ref-type="table-fn"}    365         77.4%                            
  Pathological grading                                                      66.890         \<0.001
  High/Moderate                              2042        84.4%                            
  Poor/undifferentiation                     713         70.5%                            
  Unknown                                    106         66.9%                            
  Histological Type                                                         18.858         \<0.001
  Adenocarcinoma                             2267        82.0%                            
  Mucinous/Signet ring cancer                587         74.1%                            
  AJCC stage                                                               289.312         \<0.001
  I                                          251         98.8%                            
  II                                         1184        90.3%                            
  III                                        1426        68.7%                            
  No. of LNs dissected                                                      25.506         \<0.001
  \<12                                       833         74.8%                            
  ≥12                                        2028        82.6%                            

\*including other(American Indian/AK Native, Asian/Pacific Islander) and unknowns.

10.1371/journal.pone.0102004.t003

###### Multivariate Cox model analyses of prognostic factors of CC.

![](pone.0102004.t003){#pone-0102004-t003-3}

  Variable                                   Hazard Ratio       95%CI          P
  ----------------------------------------- -------------- --------------- ---------
  Age                                                                        0.041
  ≤25                                           1.000         Reference    
  26--30                                        0.797       0.569--1.116     0.186
  31--35                                        0.681       0.497--0.932     0.017
  36--40                                        0.676       0.503--0.909     0.010
  Race                                                                       0.007
  Caucasian                                     1.000         Reference    
  African American                              1.381       1.130--1.687     0.002
  Others[\*](#nt103){ref-type="table-fn"}       1.114       0.885--1.403     0.357
  Pathological grading                                                      \<0.001
  High/Moderate                                 1.000         Reference    
  Poor/undifferentiation                        1.520       1.286--1.797    \<0.001
  Unknown                                       2.137       1.526--2.993    \<0.001
  Histological Type                                                          0.057
  Adenocarcinoma                                1.000         Reference    
  Mucinous/Signet ring cancer                   1.191       0.995--1.427   
  AJCC stage                                                                \<0.001
  I                                             1.000         Reference    
  II                                            5.076       2.241--11.496   \<0.001
  III                                           17.047      7.609--38.190   \<0.001
  No. of LNs dissected                                                      \<0.001
  \<12                                          1.000         Reference    
  ≥12                                           0.620       0.529--0.727   

\*including other (American Indian/AK Native, Asian/Pacific Islander) and unknowns.

Discussion {#s4}
==========

Many studies evaluated biological behavior and risk of relapse and death in young patients with CC [@pone.0102004-OConnell2], [@pone.0102004-Neufeld1], [@pone.0102004-Karsten1], [@pone.0102004-Li1], [@pone.0102004-Cusack1], [@pone.0102004-Marble1], [@pone.0102004-Li2], [@pone.0102004-Schellerer1]. Despite much research, CC in the young has not been well characterized, due to conflicting data in the literature. For example, various studies have reported poorer prognosis among young patients with CC [@pone.0102004-Taylor1], [@pone.0102004-Cusack1], [@pone.0102004-Marble1], but our previous study and some recently published articles showed better CCSS in young patients after surgery than elderly ones [@pone.0102004-Li1], [@pone.0102004-Li2], [@pone.0102004-Schellerer1]. These inconsistent could be explained by: First, the current definition of young CRC patients remains controversial. Although majority of studies in the literature used the cutoff age of 40 years to denote a young patients with CC [@pone.0102004-OConnell2], [@pone.0102004-Neufeld1], [@pone.0102004-Karsten1], [@pone.0102004-Taylor1], [@pone.0102004-Li1], some other studies used the cutoff age of 30 years [@pone.0102004-Neufeld1], [@pone.0102004-Kam1], 25 years [@pone.0102004-Kaplan1] or others [@pone.0102004-BenIshay1], [@pone.0102004-Mitry1], [@pone.0102004-You1]. Second, young age consisted wide age range of population, which maybe an inherent characteristic of heterogeneous, different composition of young subgroup may cause different results. Nonetheless no studies have evaluated both the clinicopathological features and CCSS of different strata of young patients with CC. In a smaller recent study, Schellerer et al evaluated the clinicopathologic characteristics and treatment outcomes of young patients (≤25 years) with CRC, and found sex and symptoms (abdominal pain and rectal bleeding) were significantly differed between child-adolescent (0 to 19 year) and young adult (20 to 25 year) and there also higher percentage of Dukes C/D stage and more proportion of moderated/poor differentiate cancer in young adult group [@pone.0102004-Kaplan1], but authors didn\'t make statistical analysis of these and didn\'t consider the age-strata of patients between 26 and 40 years.

In this cohort, we found there were more patients with high/moderate grading, more adenocarcinoma and earlier stage (I/II) tumor, but smaller number of LNs retrieval and metastases with age increased in young patients, this difference had statistical significance. Patients with very young group (18--25 year) had similar 5 year CCSS with 26--30 year group, but significant lower than 31--35 and 36--40 year group, which confirmed our hypothesis that young patients was an inherently heterogeneous. In fact this did not exist in rectal cancer ([Figure S1](#pone.0102004.s001){ref-type="supplementary-material"}). Anders et al also revealed no significant differences in breast cancer in disease free survival among age groups younger than 30, 30--34, and 35--39 years [@pone.0102004-Anders1].

Although this is a large population-based study, it has several potential limitations. First, the SEER database lacks several important tumor characteristics (eg, perineural invasion and lymphovascular invasion), cancer therapy (neoadjuvant and adjuvant, quality of surgery). Thus, our analyses could not adjust for these potential confounding factors. Second, this data include only patients who had undergone surgical resection for CC. As such, this group of patients can not represent CC patients who had irresectable tumors or refused surgical intervention for various reasons. Still, our study has its convincing power for its larger population based study.

In conclusion, our analysis of the SEER database revealed that the group of young patients with CC at age 18--40 years is essentially a heterogeneous group. Patients at age 31--35, 36--40 groups have more favorable clinicopathologic characteristics and better CCSS than below 30 years.

Supporting Information {#s5}
======================

###### 

Survival curves in rectal cancer patients according to four age subgroups. Group 1 vs.group 2, *χ2 = 0.922, P = 0.337*; group 1 vs. group 3, *χ2 = 0.001, P = 0.973*. group 1 vs. group 4, *χ2 = 0.135, P = 0.714*; group 2 vs. group 3, *χ2 = 3.530, P = 0.060. group 3* vs. group 4, *χ2 = 1.535, P = 0.215*; group 3 vs. group 4, *χ2 = 1.105, P = 0.293*.

(TIF)

###### 

Click here for additional data file.
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